Skip to main content
LEXX
NASDAQ Life Sciences

Lexaria Bioscience Receives Nasdaq Delisting Warning for Sub-$1.00 Bid Price

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.725
Mkt Cap
$18.043M
52W Low
$0.46
52W High
$1.911
Market data snapshot near publication time

summarizeSummary

Lexaria Bioscience Corp. received a Nasdaq deficiency notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period to avoid delisting.


check_boxKey Events

  • Nasdaq Bid Price Deficiency Notice

    On February 4, 2026, Lexaria Bioscience Corp. received a letter from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.

  • 180-Day Compliance Period

    The company has 180 calendar days, until August 3, 2026, to regain compliance by having its common stock close at or above $1.00 for at least 10 consecutive business days.

  • Potential for Reverse Stock Split

    If compliance is not met within the initial period, the company may be eligible for an additional 180-day period, which could necessitate a reverse stock split to cure the deficiency.

  • Context of Going Concern Warning

    This delisting notice follows a recent 10-Q filing on January 13, 2026, where the company expressed substantial doubt about its ability to continue as a going concern, intensifying financial and operational concerns.


auto_awesomeAnalysis

Lexaria Bioscience Corp. has received a formal notice from Nasdaq regarding its non-compliance with the minimum $1.00 bid price requirement. This is a critical development, especially following the company's recent 10-Q filing on January 13, 2026, which disclosed substantial doubt about its ability to continue as a going concern. The delisting notice adds significant pressure and uncertainty, as maintaining a Nasdaq listing is crucial for investor confidence and liquidity, particularly for a micro-cap company. While the company has 180 days to regain compliance, potentially through a reverse stock split, the underlying financial challenges highlighted by the 'going concern' warning suggest a difficult path ahead. Investors should monitor the company's efforts to address both its financial stability and its Nasdaq listing status.

At the time of this filing, LEXX was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18M. The 52-week trading range was $0.46 to $1.91. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed LEXX - Latest Insights

LEXX
Apr 21, 2026, 9:10 AM EDT
Source: The newswire.ca
Importance Score:
7
LEXX
Apr 13, 2026, 1:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
LEXX
Apr 10, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
7
LEXX
Apr 07, 2026, 9:10 AM EDT
Source: Access Newswire
Importance Score:
8
LEXX
Mar 26, 2026, 9:20 AM EDT
Source: Access Newswire
Importance Score:
7
LEXX
Feb 06, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
LEXX
Jan 14, 2026, 5:26 PM EST
Filing Type: 424B3
Importance Score:
7
LEXX
Jan 13, 2026, 3:20 PM EST
Filing Type: 10-Q
Importance Score:
8